ClinicalTrials.Veeva

Menu
K

KC Care Health Center | Midtown South

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lenacapavir
Islatravir
Ulonivirine
Bictegravir
ISL
GS-1720
emtricitabine
Doravirine
DOR
MK-8591B-062

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 12 total trials
Locations recently updated

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral...

Enrolling
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Drug: ISL/ULO
Drug: ULO

The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with...

Active, not recruiting
HIV Infection
Drug: DOR/ISL

Investigators are trying to find better treatments for people with HIV-1. In this clinical study, investigators want to see how well a new treatment...

Active, not recruiting
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Drug: BIC/FTC/TAF
Drug: ULO

The main purpose of the study is to evaluate the effectiveness, of the ACCELERATE model of care to achieve HIV viral suppression at Week 24. The stud...

Enrolling
Noncompliance, Patient
ART
Other: The Accelerate model of care
Drug: bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg

This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that...

Enrolling
HIV-1-infection
Drug: Standard of Care
Drug: GS-3242

The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of a...

Active, not recruiting
Pre-Exposure Prophylaxis of HIV Infection
Drug: Sub-cutaneous (SC) Lenacapavir (LEN)
Drug: PTM Oral LEN

The goal of this clinical study is to learn more about the experimental drugs GS-1720 and GS-4182; to compare the combination of GS-1720 and GS-4182...

Active, not recruiting
HIV-1-Infection
Drug: Placebo to Match BVY
Drug: Placebo to Match GS1720/GS-4182 FDC

The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regi...

Active, not recruiting
HIV-1-infection
Drug: B/F/TAF
Drug: PTM ISL/LEN

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose c...

Active, not recruiting
HIV-1-infection
Drug: B/F/TAF
Drug: Placebo to match B/F/TAF

Trial sponsors

Gilead Sciences logo
Merck Sharp & Dohme (MSD) logo
Ann & Robert H Lurie Children's Hospital of Chicago logo
University of Missouri (MU) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems